Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült Államok2. fázis

A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)

A legfontosabb adatok

Ki végzi
Tiziana Life Sciences LTD
Hol
Boston (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
2. fázis
Résztvevők
5 fő, tervezett
Kezdés
2025. máj. 19.
Várható befejezés
2027. ápr. 1.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Foralumab Nasal
A regiszteradat frissítve
2026. június 10.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with multiple system atrophy (MSA) to test Foralumab Nasal, a nasal spray. There is a 6-month watch-only phase, then 6 months of treatment.

Életkor
30 to 85 years
Nem
All sexes
A betegség stádiuma
Clinically Established or Clinically Probable MSA, by the 2022 MDS diagnostic criteria.
Korábbi kezelés
Must be on stable dopaminergic treatment for at least 4 weeks. No systemic corticosteroids in the past four weeks. No chronic immunosuppressives such as interferon, fingolimod or natalizumab in the past 90 days. No nasal corticosteroids or nasal antihistamines in the past 30 days. Vaccines must be up to date.
Biomarker vagy leletérték
Hemoglobin ≥ 9 g/dL and platelets ≥ 100 x 109 cells/L. People who are low-affinity binders for TSPO PET tracers cannot join.

A részvétel fő kizáró okai

  • Another cause of Parkinsonism or another known nerve disease
  • Pregnant or breastfeeding
  • Significant memory or thinking problems (MoCA score of 20 or less)
  • Positive test for HIV, hepatitis B, hepatitis C or EBV IgM, or a past cancer
  • Serious heart problem in the last 6 months, or nose problems such as nasal polyps or chronic rhinitis

A regiszter feltételei, szó szerint

Mind a 36 feltétel megnézéseKevesebb

Ki vehet részt

  • Subjects with a clinical diagnosis of Clinically Established or Clinically Probable Multiple System Atrophy in accordance with 2022 MDS diagnostic criteria
  • Age 30 to 85 years, at the time of signing the informed consent
  • Stable dopaminergic treatment for at least 4 weeks before enrollment
  • Adequate hematologic parameters without ongoing transfusion support: Hemoglobin (Hb) ≥ 9 g/dL; Platelets ≥ 100 x 109 cells/L
  • Creatinine ≤ 1.5 x the upper limit of normal (ULN), or calculated creatinine clearance ≥ 60 mL/minute x 1.73 m2 per the Cockcroft-Gault formula
  • Total bilirubin ≤ 2 times the upper limit of normal (ULN) unless due to Gilbert's disease
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 times ULN
  • QT interval corrected for rate (QTcF) ≤ 470 msec for women and ≤ 450 msec for men on the ECG obtained at Screening
  • Negative urine pregnancy test within 7 days prior to the first dose of study therapy for women of child-bearing potential (WCBP), defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months). Sexually active WCBP and male patients must agree to use highly effective methods to avoid pregnancy (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) throughout the study and for 90 days after the completion of study treatment
  • Patients whose immunizations are fully up to date at the Screening, according to the assessment of their primary care physician and neurologist
  • Ability to provide written informed consent

Ki nem vehet részt

  • Systemic corticosteroid treatment in the past four weeks (excluding nasal or local treatment)
  • Brain MRI indicative of significant abnormalities that interfere with PET-MRI co-registration (i.e., large prior hemorrhage or multiple infarcts)
  • Treatment with chronic immunosuppressives such as interferon, glatiramer acetate, fingolimod, Siponimod, dimethyl fumarate, or natalizumab within the past 90 days
  • Inability to tolerate nasally administered medications
  • Nasal corticosteroids, nasal antihistamines, nasal flu dosing within the past 30 days, or anticipated need during the study
  • A recent clinically significant active infection requiring treatment with antibiotics or other anti-infective agents within the past 15 days
  • Individuals with significant cognitive impairment (i.e., MoCA score less than or equal to 20)
  • Patients who test positive for human immunodeficiency virus (HIV), hepatitis B virus surface antigen (HBsAg), hepatitis C virus (HCV) or positive Epstein-Barr virus (EBV) IgM at the Screening Visit
  • Past medical history of a hematologic or solid malignancy
  • Chronic rhinitis, deviated septum, nasal polyps, history of sinusitis treated within the past 8 months
  • Inflammatory bowel disease, rheumatoid arthritis, systemic lupus erythematosus, primary Sjögren's Syndrome, asthma, or type 1 diabetes
  • Patients with a history of gadolinium allergy
  • Any other medical or surgical intervention or other condition which, in the opinion of the Principal Investigator, could compromise adherence to study requirements or confound the interpretation of study results
  • Active COVID-19 disease
  • COVID-19 vaccine within past 10 days or any other vaccine within past 7 days (at dosing)
  • Serious cardiac condition within the last 6 months, such as uncontrolled arrhythmia, myocardial infarction, unstable angina, or heart disease defined by the New York Heart Association (NYHA) Class III or Class IV or hereditary long QT syndrome
  • Concomitant medication(s) that may cause QTc prolongation or induce Torsades de Pointes, except for antimicrobials that are used as standard of care to prevent or treat infections and other such drugs that are considered by the Investigator to be essential for patient care
  • Neutropenia or an absolute neutrophil count of < 1,000 cells/mL or other indicators of severe immunosuppression
  • Severe lymphopenia or an absolute lymphocyte count of < 500 cells/mL
  • Diagnosis or suspicion of other cause for Parkinsonism or a known alternate neurologic diagnosis
  • Female patient who is pregnant, lactating, breastfeeding, or planning to become pregnant during study
  • Individuals with claustrophobia who cannot tolerate the study procedures
  • Non-MRI-compatible implanted devices
  • Low-affinity binders for translocator protein (TSPO) PET ligands
  • Unable or unwilling to comply with protocol requirements

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 30 és 85 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • Brigham and Women's HospitalBoston, Egyesült ÁllamokContact: BWH Movement Disorders Research GroupRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

A Phase 2a Study of Foralumab Nasal in Patients with Multiple System Atrophy (MSA)

A vizsgálat csoportja

  • Foralumab NasalA vizsgált kezelés

    This study includes a 6-month observational lead-in phase followed by a 6-month open-label treatment phase with Foralumab Nasal.

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase 2a Study to Evaluate Microglial Activation, Safety, and Clinical Effects of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT06868628: ki vehet részt
A regiszteradat frissítve
2026. június 10.